drugset / Trial / NCT02665143
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
Timeline
- Start
- 2016-07-21
- Primary completion
- 2021-03-08
- Completion
- 2021-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 150 mg | — |
| Subject | Nintedanib | Small molecule | 200 mg | — |
| Background | Cytarabine | Small molecule | 667 mg/m2 | Intravenous |
| Background | Idarubicin | Small molecule | 12 mg/m2 | — |